Targets › NSP5
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.
Open in Phaseline: the race on NSP5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Unity Health Toronto | Paxlovid SARS-CoV-2 protease inhibitor | 3CL, NSP5 | Phase 3 | COVID-19 | – |
COVID-19 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.